Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd., explained in plain language.
-
New drug aims to calm painful skin flares in hidradenitis suppurativa
Disease control Recruiting nowThis early-stage trial is testing a new drug called HB0043 in 15 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. The drug is a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) to reduc…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody drug HB0056 begins first human safety trial
Knowledge-focused Recruiting nowThis early-stage trial is testing the safety of a single dose of HB0056, a new bispecific antibody, in 46 healthy adults aged 18 to 55. Participants are randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves…
Phase: PHASE1 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:18 UTC